

# Livtency (maribavir)

| Override(s)                           | Approval Duration |
|---------------------------------------|-------------------|
| Prior Authorization<br>Quantity Limit | 2 months          |

| Medications                        | Quantity Limit    |
|------------------------------------|-------------------|
| Livtency (maribavir) 200mg tablets | 4 tablets per day |

May approve up to 12 tablets per day when co-administered with carbamazepine, phenytoin or phenobarbital.

## **APPROVAL CRITERIA**

Requests for Livtency (maribavir) may be approved if the following criteria are met:

- I. Individual is using to treat cytomegalovirus (CMV) infection or disease; AND
- II. Individual is a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) recipient; AND
- III. Individual is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.

Livtency (maribavir) may not be approved for the following:

- I. Prevention of CMV infection/disease; OR
- II. Used in combination with ganciclovir or valganciclovir.

## **Key References:**

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 5, 2022.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.